Original news and analysis on international IP policy
The first biosimilar of the blockbuster breast cancer drug trastuzumab is being prepared for launch in United States, following a decision by the Food and Drug Administration (FDA) to approve it earlier this month. The product, Ogivri, has been created by a joint venture between US Mylan and Indian company Biocon.
The World Intellectual Property Organization Committee on Development and Intellectual Property in its latest meeting agreed on a list of items to be discussed at its next session. No consensus was found on a potential biennial conference on IP and development, but discussions are set to continue. The committee also agreed to a suggestion to invite the team conducting an independent review on the implementation of the Development Agenda Recommendations to further explain some of their own recommendations.
What do investment, trade, intellectual property, health financing, R&D, industrial and medicines regulation policy have in common? They are all important building blocks for the successful promotion of local pharmaceutical manufacturing. As more and more countries are looking into building their own pharmaceutical production capacities, they need to ensure strong policy coherence to be successful.
A delegation of heads of biotechnology companies visited Geneva this month to present the International Confederation of Biotechnology Trade Associations (ICBA). The ICBA was created in 2012, but is now looking to make its voice heard in Geneva and inform policy discussions, and is finding it is not easy to become an observer in some organisations. They also underlined the importance of intellectual property for the biotech sector, in particular to attract indispensable capital. The delegation sat down with Intellectual Property Watch’s Catherine Saez to talk about their Geneva visit.
The European Union (EU) is currently negotiating a free trade agreement (FTA) with the four founding members of Mercosur (Argentina, Brazil, Paraguay and Uruguay), which comprises a chapter on intellectual property rights (IPR). A new round of negotiations is taking place from November 29th to December 8th in Brussels[1]. Word is that they aim to announce the closure of the agreement at the next World Trade Organization (WTO) Ministerial Conference that will be held from 10-13 of December in Buenos Aires and the clock is ticking to close all the chapters before that. The authors have conducted a study that shows the adoption of the measures proposed by the EU could put the sustainability of access to health policies in Brazil at risk, as they could sharply increase public expenditures on medicines.
KAMPALA, Uganda -- The Forty-first Session of the Administrative Council of African Regional Intellectual Property Organization (ARIPO) held this month adopted the Regulations for the Implementation of the Arusha Protocol for the Protection of New Varieties of Plants, amidst protest from civil society organisations and farmer representatives.
The World Trade Organization General Council today agreed to a two-year extension for countries to adopt an amendment to the agency's intellectual property agreement intended to help small economies get affordable medical products. But a decision on non-violation complaints will be left to the December WTO ministerial in Buenos Aires.
On Monday, 27 November, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public, health innovation and intellectual property (EB142/14). The expert panel provided 33 recommendations which included 17 forward looking”high-priority actions” including on transparency and delinkage, writes Thiru Balasubramaniam.
Following a session in May hailed as the most positive in years, the World Intellectual Property Organization Committee on Development and Intellectual Property reconvenes this week. Among items to be discussed are a revised proposal by the African Group to convene a biennial international conference on IP and development, how to deal with the United Nations Sustainable Development Goals, and recommendations of an independent review of the implementation of the 2007 WIPO Development Agenda Recommendations.
NEW DELHI -- Few topics in the global health agenda are as contentious as access to affordable medicines and medical care, and expectedly, divergent views permeated the discussions at a high-level conference in New Delhi, India last week. But if there is one thing that the three-day meet made amply clear, it was this: access to affordable healthcare has emerged as a global problem, and an emerging coalition of the like-minded, cutting across the developed and developing countries, is determined to have their voices heard in international policy circles on the issue.
World Health Organization Director General Tedros Adhanom Ghebreyesus (Tedros) admonished member states at the close of this week’s special session of the WHO Executive Board charged with examining the agency’s draft work programme for 2019-2023. A trust deficit among member states leads to the multiplication of national statements, impeding efficiency, he said. Meanwhile, a number of countries called for affordable and accessible medicines, and help to manufacture generic medicines locally, while the United States pushed the role of the private sector.
The World Intellectual Property Organization program on intellectual property and environmental technology is looking for consultants to catalyze green tech transactions in the Asia-Pacific region.